In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon-γ T Cell Response
In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response...
Saved in:
| Published in | PloS one Vol. 4; no. 4; p. e5187 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
13.04.2009
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0005187 |
Cover
| Abstract | In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-gamma.
38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-gamma is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-gamma production within the range of therapeutically achievable concentrations.
The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-gamma response. |
|---|---|
| AbstractList | BACKGROUND: In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-gamma. PRINCIPAL FINDINGS: 38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-gamma is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-gamma production within the range of therapeutically achievable concentrations. CONCLUSIONS: The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-gamma response. Background In recent years, the impact of antituberculous treatment on interferon (IFN)-γ response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-γ response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-γ. Principal Findings 38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-γ is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-γ production within the range of therapeutically achievable concentrations. Conclusions The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-γ response. Background In recent years, the impact of antituberculous treatment on interferon (IFN)-γ response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-γ response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-γ. Principal Findings 38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-γ is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-γ production within the range of therapeutically achievable concentrations. Conclusions The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-γ response. In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-gamma.BACKGROUNDIn recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-gamma.38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-gamma is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-gamma production within the range of therapeutically achievable concentrations.PRINCIPAL FINDINGS38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-gamma is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-gamma production within the range of therapeutically achievable concentrations.The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-gamma response.CONCLUSIONSThe present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-gamma response. In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present study was: i) to evaluate longitudinal changes of IFN-gamma response to M. tuberculosis-specific antigens in TB patients during antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous drugs on the secretion of IFN-gamma. 38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27 patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these patients the release of IFN-gamma is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-gamma production within the range of therapeutically achievable concentrations. The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory effect on the specific IFN-gamma response. |
| Author | Mengoni, Fabio Sauzullo, Ilaria Borgo, Cosmo Del Soscia, Fabrizio Vullo, Vincenzo Iannetta, Marco Marocco, Raffaella Lichtner, Miriam Massetti, Anna Paola Mastroianni, Claudio Maria Rossi, Raffaella |
| AuthorAffiliation | 1 Department of Infectious and Tropical Diseases, “Sapienza” University, Rome, Italy University of Cape Town, South Africa 2 Infectious Diseases Unit, “Sapienza” University, Polo Pontino, Latina, Italy 3 Infectious Diseases, S.M. Goretti Hospital, Latina, Italy |
| AuthorAffiliation_xml | – name: 3 Infectious Diseases, S.M. Goretti Hospital, Latina, Italy – name: 2 Infectious Diseases Unit, “Sapienza” University, Polo Pontino, Latina, Italy – name: 1 Department of Infectious and Tropical Diseases, “Sapienza” University, Rome, Italy – name: University of Cape Town, South Africa |
| Author_xml | – sequence: 1 givenname: Ilaria surname: Sauzullo fullname: Sauzullo, Ilaria – sequence: 2 givenname: Fabio surname: Mengoni fullname: Mengoni, Fabio – sequence: 3 givenname: Miriam surname: Lichtner fullname: Lichtner, Miriam – sequence: 4 givenname: Anna Paola surname: Massetti fullname: Massetti, Anna Paola – sequence: 5 givenname: Raffaella surname: Rossi fullname: Rossi, Raffaella – sequence: 6 givenname: Marco surname: Iannetta fullname: Iannetta, Marco – sequence: 7 givenname: Raffaella surname: Marocco fullname: Marocco, Raffaella – sequence: 8 givenname: Cosmo Del surname: Borgo fullname: Borgo, Cosmo Del – sequence: 9 givenname: Fabrizio surname: Soscia fullname: Soscia, Fabrizio – sequence: 10 givenname: Vincenzo surname: Vullo fullname: Vullo, Vincenzo – sequence: 11 givenname: Claudio Maria surname: Mastroianni fullname: Mastroianni, Claudio Maria |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19365543$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUtFqFDEUDVKx7eofiAYE32adJJPMxIdCWaouVARZfQ2ZTFKzZJM1yVT2u_wPv8lsd9S2CPqUy73nnnvuuTkFRz54DcBTVM8RadGrdRijl26-Lel5XdcUde0DcII4wRXDNTm6FR-D05TWBUM6xh6B41JglDbkBNilh5_tdYDSD_AmzjHAC2O0ygkGA899tnnsdVSjC8kmuIpa5o32GQYP3-9U6KXKOlrpSn8JjI7BVz--wxVcaOfgR52KxKQfg4dGuqSfTO8MfHpzsVq8qy4_vF0uzi8rRXGTK2b40CvKWKcZUVL3mivKNZe4owMjRNX9oFTbU9wbpAai-5Y3qNHcIIMHRckMPD_wboteMbmUBMK8pk2H26YglgfEEORabKPdyLgTQVpxkwjxSsiYrXJaqHaQzWB4x4lsFFedHHrMODftfjxFhYseuEa_lbtv0rnfhKgW-0P9kiD2hxLToUrf2aRy7Dd6UMXPKN0dMXcr3n4RV-FaYMaapvgwAy8nghi-jjplsbFJFcOl12FMgrUIdwjvJ724B_y7J89u6_mzxPRTCuD1AaBiSClqI5TNMtuwl2fdv7Zt7jX_l0k_ARvW7JM |
| CitedBy_id | crossref_primary_10_1155_2012_768723 crossref_primary_10_1128_CVI_05037_11 crossref_primary_10_1155_2012_757152 crossref_primary_10_1515_hmbci_2022_0031 crossref_primary_10_3899_jrheum_120688 crossref_primary_10_1016_j_tube_2015_05_009 crossref_primary_10_1164_rccm_201208_1352OC crossref_primary_10_1016_j_jinf_2014_07_007 crossref_primary_10_1186_s13104_018_3410_x crossref_primary_10_1016_S0140_6736_10_60359_5 crossref_primary_10_1080_23744235_2017_1279747 crossref_primary_10_1016_j_vetimm_2011_07_020 crossref_primary_10_1371_journal_pone_0141033 crossref_primary_10_1111_bjd_12544 crossref_primary_10_3109_00365548_2011_611167 crossref_primary_10_1016_j_tube_2015_02_039 crossref_primary_10_3390_pathogens10060657 crossref_primary_10_1016_j_ijid_2015_05_006 crossref_primary_10_1378_chest_09_2350 crossref_primary_10_1007_s10067_012_2049_6 crossref_primary_10_1186_s12879_017_2700_6 crossref_primary_10_1093_jac_dkv023 crossref_primary_10_1016_j_tube_2015_07_002 crossref_primary_10_56951_medicinus_v33i1_5 crossref_primary_10_1128_CVI_00005_10 crossref_primary_10_1371_journal_pone_0012502 crossref_primary_10_1016_j_rmed_2010_05_011 crossref_primary_10_1097_JCMA_0000000000000071 crossref_primary_10_1186_1471_2180_11_167 crossref_primary_10_1016_j_jinf_2012_10_017 crossref_primary_10_1016_j_cimid_2012_10_010 crossref_primary_10_1016_j_clinthera_2012_03_006 crossref_primary_10_1007_s00430_015_0424_z crossref_primary_10_1186_1471_2334_11_135 crossref_primary_10_1186_1471_2334_9_182 crossref_primary_10_1016_j_cytox_2020_100028 crossref_primary_10_1097_INF_0b013e31825d0d67 crossref_primary_10_1371_journal_pone_0037436 crossref_primary_10_1016_j_ccm_2009_08_008 crossref_primary_10_1155_2013_601737 crossref_primary_10_3390_immuno1040028 |
| Cites_doi | 10.1086/381763 10.1128/CVI.00132-07 10.1038/44385 10.1371/journal.pmed.0040192 10.7326/0003-4819-149-3-200808050-00241 10.1016/S1473-3099(04)01206-X 10.1164/rccm.200604-472OC 10.1007/s15010-007-6114-z 10.1186/1471-2334-6-66 10.1086/381754 10.1164/rccm.200509-1516PP 10.1128/JCM.44.3.1197-1201.2006 10.1378/chest.06-2471 10.4049/jimmunol.167.9.5217 10.1016/S0022-1759(02)00092-3 10.2169/internalmedicine.46.0088 10.1128/IAI.69.10.6554-6557.2001 10.1086/318081 10.1038/nri778 10.1164/ajrccm.163.4.2009100 10.1164/rccm.200608-1099OC 10.1086/323044 10.1146/annurev.immunol.20.100101.151926 10.1371/journal.pone.0000183 10.1016/S0140-6736(00)05115-1 10.1016/j.diagmicrobio.2008.08.015 10.1001/jama.286.14.1740 10.1111/j.1600-6143.2007.02011.x 10.1016/S0928-8244(03)00166-4 10.1016/j.jinf.2007.02.005 10.1016/S0140-6736(03)12950-9 10.1164/rccm.200511-1783OC 10.1016/S1473-3099(07)70086-5 |
| ContentType | Journal Article |
| Copyright | 2009 Sauzullo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Sauzullo et al. 2009 |
| Copyright_xml | – notice: 2009 Sauzullo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Sauzullo et al. 2009 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1371/journal.pone.0005187 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database (Proquest) Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database (Proquest) Nursing & Allied Health Premium Advanced Technologies & Aerospace Collection ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Anti-TB Drugs and IFN-γ Assay |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1290548274 oai_doaj_org_article_c7da4df9893a4c9c8adb2699f72bf151 10.1371/journal.pone.0005187 PMC2664463 2897411761 19365543 10_1371_journal_pone_0005187 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV BBORY CGR CUY CVF ECM EIF IPNFZ NPM PV9 RIG RZL 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM ADTOC UNPAY - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c524t-6f9dbc5668e63caebe9c59e9a285d633c0bdcc7b52bf1cd3eb79414e9f1f2dc53 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Jul 31 00:48:12 EDT 2022 Wed Aug 27 01:31:05 EDT 2025 Tue Aug 19 09:24:36 EDT 2025 Tue Sep 30 16:44:55 EDT 2025 Mon Sep 08 11:22:37 EDT 2025 Fri Jul 25 10:28:48 EDT 2025 Thu Apr 03 06:55:44 EDT 2025 Thu Apr 24 22:59:41 EDT 2025 Wed Oct 01 01:47:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. cc-by Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c524t-6f9dbc5668e63caebe9c59e9a285d633c0bdcc7b52bf1cd3eb79414e9f1f2dc53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: IS FM CMM. Performed the experiments: IS FM RR RM. Analyzed the data: IS FM ML APM. Contributed reagents/materials/analysis tools: VV CMM. Wrote the paper: IS FM VV CMM. Contributed to the enrollment of patients: MI CDB VV FS. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0005187 |
| PMID | 19365543 |
| PQID | 1290548274 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1290548274 doaj_primary_oai_doaj_org_article_c7da4df9893a4c9c8adb2699f72bf151 unpaywall_primary_10_1371_journal_pone_0005187 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2664463 proquest_miscellaneous_67128127 proquest_journals_1290548274 pubmed_primary_19365543 crossref_citationtrail_10_1371_journal_pone_0005187 crossref_primary_10_1371_journal_pone_0005187 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-04-13 |
| PublicationDateYYYYMMDD | 2009-04-13 |
| PublicationDate_xml | – month: 04 year: 2009 text: 2009-04-13 day: 13 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2009 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | M Pai (ref4) 2007; 7 AA Pathan (ref15) 2001; 167 M Pai (ref25) 2007; 35 M Pai (ref36) 2006; 174 SM Kaech (ref30) 2002; 2 RA Ferrand (ref24) 2005; 9 I Sauzullo (ref31) 2008; 62 J Vekemans (ref22) 2001; 69 F Sallusto (ref26) 1999; 401 EM Leyten (ref33) 2007; 14 S Carrara (ref17) 2004; 38 L Richeldi (ref2) 2006; 174 SK Katiyar (ref32) 2008; 12 S Jones (ref11) 2007; 11 R Al-Attiyah (ref23) 2003; 38 EM Leyten (ref28) 2006; 44 Y Kobashi (ref12) 2007; 46 SM Arend (ref14) 2007; 175 A Lalvani (ref6) 2001; 357 Y Kobashi (ref34) 2008 O Manuel (ref13) 2007; 7 J Domínguez (ref35) 2008 PC Hill (ref37) 2007; 4(6) K Ewer (ref38) 2006; 174 M Pai (ref1) 2004; 4 R Hussain (ref10) 2002; 264(1–2) EL Corbett (ref40) 2006; 10 K Ewer (ref9) 2003; 361 GH Mazurek (ref8) 2001; 286 PC Hill (ref39) 2007; 2(1) A Lalvani (ref16) 2001; 183 AM Aiken (ref18) 2006; 6 T Ulrichs (ref20) 2000; 4 M Pai (ref5) 2008; 149 BA Wu-Hsieh (ref21) 2001; 33 J Sprent (ref29) 2002; 20 A Lalvani (ref3) 2007; 13 A Lalvani (ref7) 2001; 163 K Dheda (ref19) 2007; 55 A Lalvani (ref27) 2004; 38 17564487 - PLoS Med. 2007 Jun;4(6):e192 11144463 - Int J Tuberc Lung Dis. 2000 Dec;4(12):1181-3 14522460 - FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):249-56 10537110 - Nature. 1999 Oct 14;401(6754):708-12 11673535 - J Immunol. 2001 Nov 1;167(9):5217-25 12001996 - Nat Rev Immunol. 2002 Apr;2(4):251-62 17878640 - Intern Med. 2007;46(18):1543-9 11594899 - JAMA. 2001 Oct 10;286(14):1740-7 16799072 - Am J Respir Crit Care Med. 2006 Oct 1;174(7):831-9 17448540 - J Infect. 2007 Aug;55(2):169-73 17264885 - PLoS One. 2007;2(1):e183 11438135 - Lancet. 2001 Jun 23;357(9273):2017-21 11565073 - Clin Infect Dis. 2001 Oct 15;33(8):1336-40 11133379 - J Infect Dis. 2001 Feb 1;183(3):469-77 16799073 - Am J Respir Crit Care Med. 2006 Oct 1;174(7):736-42 15567126 - Lancet Infect Dis. 2004 Dec;4(12):761-76 11861612 - Annu Rev Immunol. 2002;20:551-79 17941955 - Am J Transplant. 2007 Dec;7(12):2797-801 18593687 - Ann Intern Med. 2008 Aug 5;149(3):177-84 17401714 - Infection. 2007 Apr;35(2):98-103 17521596 - Lancet Infect Dis. 2007 Jun;7(6):428-38 14986262 - Clin Infect Dis. 2004 Mar 1;38(5):754-6 12686038 - Lancet. 2003 Apr 5;361(9364):1168-73 14986263 - Clin Infect Dis. 2004 Mar 1;38(5):757-9 18812044 - Int J Tuberc Lung Dis. 2008 Oct;12(10):1146-52 19026511 - Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51 17565023 - Chest. 2007 Jun;131(6):1898-906 18848730 - J Infect. 2009 Mar;58(3):197-204 16158897 - Int J Tuberc Lung Dis. 2005 Sep;9(9):1034-9 17170386 - Am J Respir Crit Care Med. 2007 Mar 15;175(6):618-27 16517931 - J Clin Microbiol. 2006 Mar;44(3):1197-201 16573826 - BMC Infect Dis. 2006;6:66 18930368 - Diagn Microbiol Infect Dis. 2008 Dec;62(4):395-401 16690977 - Am J Respir Crit Care Med. 2006 Aug 1;174(3):349-55 17507543 - Clin Vaccine Immunol. 2007 Jul;14(7):880-5 11282752 - Am J Respir Crit Care Med. 2001 Mar;163(4):824-8 11553606 - Infect Immun. 2001 Oct;69(10):6554-7 17958980 - Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5 12191514 - J Immunol Methods. 2002 Jun 1;264(1-2):95-108 |
| References_xml | – volume: 38 start-page: 757 year: 2004 ident: ref27 article-title: Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? publication-title: Clin Infect Dis doi: 10.1086/381763 – volume: 14 start-page: 880 year: 2007 ident: ref33 article-title: Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00132-07 – volume: 401 start-page: 708 year: 1999 ident: ref26 article-title: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. publication-title: Nature doi: 10.1038/44385 – volume: 4(6) start-page: e192 year: 2007 ident: ref37 article-title: Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. publication-title: PloS Med doi: 10.1371/journal.pmed.0040192 – volume: 149 start-page: 177 year: 2008 ident: ref5 article-title: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. publication-title: Ann Intern Med doi: 10.7326/0003-4819-149-3-200808050-00241 – volume: 4 start-page: 761 year: 2004 ident: ref1 article-title: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(04)01206-X – volume: 174 start-page: 349 year: 2006 ident: ref36 article-title: Serial testing of health care workers for tuberculosis using interferon-gamma assay. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200604-472OC – volume: 35 start-page: 98 year: 2007 ident: ref25 article-title: Sensitivity of a whole blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during antituberculosis treatment. publication-title: Infection doi: 10.1007/s15010-007-6114-z – volume: 6 start-page: 66 year: 2006 ident: ref18 article-title: Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. publication-title: BMC Infect Dis doi: 10.1186/1471-2334-6-66 – volume: 38 start-page: 754 year: 2004 ident: ref17 article-title: Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. publication-title: Clin Infect Dis doi: 10.1086/381754 – volume: 174 start-page: 736 year: 2006 ident: ref2 article-title: An update on the diagnosis of tuberculosis infection. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200509-1516PP – volume: 44 start-page: 1197 year: 2006 ident: ref28 article-title: Use of enzyme-linked immunospot assay with Mycobacterium tuberculosis-specific peptides for diagnosis of recent infection with M tuberculosis after accidental laboratory exposure. publication-title: J Clin Microbiol doi: 10.1128/JCM.44.3.1197-1201.2006 – volume: 13 start-page: 1898 year: 2007 ident: ref3 article-title: Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. publication-title: Chest doi: 10.1378/chest.06-2471 – volume: 167 start-page: 5217 year: 2001 ident: ref15 article-title: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4+ T cells in Mycobacterium tuberculosis–infected individuals: association with clinical disease state and effect of treatment. publication-title: J Immunol doi: 10.4049/jimmunol.167.9.5217 – volume: 11 start-page: 1190 year: 2007 ident: ref11 article-title: Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. publication-title: Int J Tuberc Lung Dis – volume: 264(1–2) start-page: 95 year: 2002 ident: ref10 article-title: Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. publication-title: J Immunol Methods doi: 10.1016/S0022-1759(02)00092-3 – volume: 46 start-page: 1543 year: 2007 ident: ref12 article-title: Usefulness of Quanti-FERON TB-2G, a diagnostic method for latent tuberculosis infection, in a contact investigation of health care workers. publication-title: Intern Med doi: 10.2169/internalmedicine.46.0088 – volume: 69 start-page: 6554 year: 2001 ident: ref22 article-title: Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. publication-title: Infect Immun doi: 10.1128/IAI.69.10.6554-6557.2001 – volume: 183 start-page: 469 year: 2001 ident: ref16 article-title: Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. publication-title: J Infect Dis doi: 10.1086/318081 – volume: 2 start-page: 251 year: 2002 ident: ref30 article-title: Effector and memory T-cell differentiation: implications for vaccine development. publication-title: Nat Rev Immunol doi: 10.1038/nri778 – volume: 163 start-page: 824 year: 2001 ident: ref7 article-title: Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.163.4.2009100 – volume: 175 start-page: 618 year: 2007 ident: ref14 article-title: Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200608-1099OC – volume: 9 start-page: 1034 year: 2005 ident: ref24 article-title: Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. publication-title: Int J Tuberc Lung Dis – volume: 33 start-page: 1336 year: 2001 ident: ref21 article-title: Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. publication-title: Clin Infect Dis doi: 10.1086/323044 – volume: 10 start-page: S231 year: 2006 ident: ref40 article-title: Tuberculosis infection in African nursing students: Tuberculin skin test compared to ELISPOT conversion rates. publication-title: Int J Tuberc Lung Dis – volume: 20 start-page: 551 year: 2002 ident: ref29 article-title: T cell memory. publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.20.100101.151926 – volume: 2(1) start-page: e183 year: 2007 ident: ref39 article-title: Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. publication-title: PloS ONE doi: 10.1371/journal.pone.0000183 – volume: 357 start-page: 2017 year: 2001 ident: ref6 article-title: Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. publication-title: Lancet doi: 10.1016/S0140-6736(00)05115-1 – volume: 62 start-page: 395 year: 2008 ident: ref31 article-title: QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.08.015 – volume: 286 start-page: 1740 year: 2001 ident: ref8 article-title: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. publication-title: JAMA doi: 10.1001/jama.286.14.1740 – volume: 7 start-page: 2797 year: 2007 ident: ref13 article-title: Comparison of Quanti-FERON-TB Gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2007.02011.x – year: 2008 ident: ref34 article-title: Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. publication-title: J Infect – volume: 38 start-page: 249 year: 2003 ident: ref23 article-title: Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. publication-title: FEMS Immunol Med Microbiol doi: 10.1016/S0928-8244(03)00166-4 – year: 2008 ident: ref35 article-title: T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. publication-title: Diagn Microbiol Infect Dis – volume: 55 start-page: 169 year: 2007 ident: ref19 article-title: Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. publication-title: J Infect doi: 10.1016/j.jinf.2007.02.005 – volume: 361 start-page: 1168 year: 2003 ident: ref9 article-title: Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. publication-title: Lancet doi: 10.1016/S0140-6736(03)12950-9 – volume: 4 start-page: 1181 year: 2000 ident: ref20 article-title: Numbers of IFN gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. publication-title: Int J Tuberc Lung Dis – volume: 174 start-page: 831 year: 2006 ident: ref38 article-title: Dynamic antigen specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200511-1783OC – volume: 12 start-page: 1146 year: 2008 ident: ref32 article-title: Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. publication-title: Int J Tuberc Lung Dis – volume: 7 start-page: 428 year: 2007 ident: ref4 article-title: T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(07)70086-5 – reference: 18930368 - Diagn Microbiol Infect Dis. 2008 Dec;62(4):395-401 – reference: 11673535 - J Immunol. 2001 Nov 1;167(9):5217-25 – reference: 17507543 - Clin Vaccine Immunol. 2007 Jul;14(7):880-5 – reference: 14986262 - Clin Infect Dis. 2004 Mar 1;38(5):754-6 – reference: 16517931 - J Clin Microbiol. 2006 Mar;44(3):1197-201 – reference: 17958980 - Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5 – reference: 17521596 - Lancet Infect Dis. 2007 Jun;7(6):428-38 – reference: 17878640 - Intern Med. 2007;46(18):1543-9 – reference: 17565023 - Chest. 2007 Jun;131(6):1898-906 – reference: 18812044 - Int J Tuberc Lung Dis. 2008 Oct;12(10):1146-52 – reference: 14986263 - Clin Infect Dis. 2004 Mar 1;38(5):757-9 – reference: 16690977 - Am J Respir Crit Care Med. 2006 Aug 1;174(3):349-55 – reference: 17264885 - PLoS One. 2007;2(1):e183 – reference: 11594899 - JAMA. 2001 Oct 10;286(14):1740-7 – reference: 16158897 - Int J Tuberc Lung Dis. 2005 Sep;9(9):1034-9 – reference: 18848730 - J Infect. 2009 Mar;58(3):197-204 – reference: 17401714 - Infection. 2007 Apr;35(2):98-103 – reference: 11133379 - J Infect Dis. 2001 Feb 1;183(3):469-77 – reference: 16573826 - BMC Infect Dis. 2006;6:66 – reference: 17448540 - J Infect. 2007 Aug;55(2):169-73 – reference: 12001996 - Nat Rev Immunol. 2002 Apr;2(4):251-62 – reference: 11438135 - Lancet. 2001 Jun 23;357(9273):2017-21 – reference: 10537110 - Nature. 1999 Oct 14;401(6754):708-12 – reference: 17941955 - Am J Transplant. 2007 Dec;7(12):2797-801 – reference: 17564487 - PLoS Med. 2007 Jun;4(6):e192 – reference: 11861612 - Annu Rev Immunol. 2002;20:551-79 – reference: 11144463 - Int J Tuberc Lung Dis. 2000 Dec;4(12):1181-3 – reference: 11282752 - Am J Respir Crit Care Med. 2001 Mar;163(4):824-8 – reference: 11565073 - Clin Infect Dis. 2001 Oct 15;33(8):1336-40 – reference: 17170386 - Am J Respir Crit Care Med. 2007 Mar 15;175(6):618-27 – reference: 11553606 - Infect Immun. 2001 Oct;69(10):6554-7 – reference: 14522460 - FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):249-56 – reference: 19026511 - Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51 – reference: 12191514 - J Immunol Methods. 2002 Jun 1;264(1-2):95-108 – reference: 16799072 - Am J Respir Crit Care Med. 2006 Oct 1;174(7):831-9 – reference: 15567126 - Lancet Infect Dis. 2004 Dec;4(12):761-76 – reference: 18593687 - Ann Intern Med. 2008 Aug 5;149(3):177-84 – reference: 12686038 - Lancet. 2003 Apr 5;361(9364):1168-73 – reference: 16799073 - Am J Respir Crit Care Med. 2006 Oct 1;174(7):736-42 |
| SSID | ssj0053866 |
| Score | 2.1576834 |
| Snippet | In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely... Background In recent years, the impact of antituberculous treatment on interferon (IFN)-γ response to Mycobacterium tuberculosis antigens has been widely... BACKGROUND: In recent years, the impact of antituberculous treatment on interferon (IFN)-gamma response to Mycobacterium tuberculosis antigens has been widely... Background In recent years, the impact of antituberculous treatment on interferon (IFN)-γ response to Mycobacterium tuberculosis antigens has been widely... |
| SourceID | plos doaj unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e5187 |
| SubjectTerms | Adolescent Adult Aged Antigens Antigens, Bacterial - immunology Antitubercular Agents - immunology Antitubercular Agents - therapeutic use Blood & organ donations CD4 antigen CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - secretion CD8 antigen CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - secretion Clinical medicine Drugs Effector cells ESAT-6 antigen Female Humans Immunological memory Incubation Infections Infectious Diseases Infectious Diseases/Bacterial Infections Infectious Diseases/Respiratory Infections Interferon Interferon-gamma - immunology Interferon-gamma - secretion Lymphocytes Lymphocytes T Male Memory cells Mycobacterium tuberculosis Mycobacterium tuberculosis - immunology Patients Pharmacology Reversion Skin T cell receptors Therapy Tropical diseases Tuberculosis Tuberculosis - drug therapy Tuberculosis - immunology Young Adult γ-Interferon |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZQL3BBlK0DBXzgAAdPG9uxx0dAVAUJTq3UW-QVRso4o2SmqP-e58QJM6JSOXCLvCT2W-LP9vNnhN5KDRhAe0-41YJwYx0xhfaEMm0kwGtdmrSg_-27OL_kX6_Kq52rvlJM2EAPPAjuxEqnuQsKxlXNrbIL7QwVSgVJTSj6w9MUhrFxMjX8g8GLhcgH5ZgsTrJe5usm-nkPW1II3c5A1PP1J37Tuuluw5p_h0ze38a1vvml63pnPDp7hB5mIIk_DB04RPd8fIwOs6t2-F3mk37_BNVfIr5eXjdYR4eX6XnTNjgHcuAmQHqKFzC-tVto2LLDU_Q5biJe3Vjw-Z7TGb6X6CXa4Nsmkh96tdL4Aqe1f9wOsbb-Kbo8-3zx6ZzkSxaILSnfEBGUMxZA3cILZjXoVNlSeaXponSCMXtqnLXSlEnc1jEPKuQF9yoUgTpbsmfoIIJYjxBW1J9y0HTwgHPMIigv4dUFh1rGcMlmiI0Sr2xmIE8XYdRVv60mYSYyyK5KeqqynmaITLXWAwPHHeU_JmVOZRN_dp8AVlVlq6rusqoZOkqmMH6gq9JyXZkoU_kMHY_mcXv2mykbPDWpQEffbLtKyLRrSaGBzwdb-tMdxQTAOhCQ3LOyvT7s58Tlz54LHPAVTOih5nyyx3-S0ov_IaWX6MG4uVawY3Swabf-FWC0jXndu-NvM0VCcA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtQwFLXKdAEbRHl1SgEvWMDC0yZ27PECobZqVZA6QtUUdRf5FRgpSoZkpqjfxX_wTVw7zrQjKmAXxXES34dz4nt9LkJvhAIMoJwjzChOmDaW6EQ5klKlBcBrlWm_oH824acX7NNldrmBJv1eGJ9W2c-JYaK2tfFr5Ht-vSTznJXsw_w78VWjfHS1L6GhYmkF-z5QjN1Dm35KZgO0eXg8-Xzez83g3ZzHDXRUJHtRX6N5XblRgDM-te7WByrw-Hve07Ju78Kgf6ZS3l9Wc3X9Q5Xlre_UySP0MAJMfNBZxBbacNVjtBVduMVvI8_0uydo9rHCX2ZXNVaVxeF40dS4ozNucV3gA7-Fd6ldY5bwYrMWT_usdFxX-OzawFwQuJ7heWFlsXBNXZFfP_EUH7myxOddAq57ii5OjqdHpyRWXiAmS9mC8EJabQDpjR2nRoGipcmkkyodZ5ZTava1NUboLNVFYix1oFeWMCeLpEityegzNKhAptsIy9TtM1B_4QD86HEhnYBbJwx6ac0EHSLaizs3kZbcV8co8xBrE_B70gku90rKo5KGiKx6zTtajn9cf-g1ubrWk2qHE3XzNY8-mhthFbOFBAinmJFmrKxOuZSF8MPMkiHa9nbQP6DNb2xyiHZ727i7-fWqGdzXx2RU5eplm3PhQ5kpvODzzpBuhiMpB6wHAhJrJrY2hvWWavYtEIQD6IK_fOg5Whnjf0lp5--jeIEe9LG0hO6iwaJZupcAyRb6VfSz3_hmPbs priority: 102 providerName: ProQuest – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLXKdAEboLw6UMALFrBwOolf4-VQURWkVghNUVmgyHYcMSJKRpMEVBb8FP_BN3GdOAMDRcCCXRT7OvbxjXPsa58g9Ehq4ADaOcKsFoQZmxETa0cSqo0Eeq258Qv6xyfi6JS9OONnW-jtcBYmIAhzxKKqu0i-v6hKtx-Q3Pd6RX30NIqpjAeLaAmZoo6SwAjeKQ75lbHGH0C6hLYFh8n1CG2fnrycvekjzQkRyYSG43S_K2njc9Wp-nsVVKjSRYz0142Vl9tyqc8_6qL44at1eA19Htrbb1Z5H7WNieynn6Qg_xsg19HVwHfxrC9lB2258gbaCSNKjR8H2esnN9HieYlfLz5UWJcZ7q6bVYV7deUaVzme-RPFrXEr20LdFjWeD5vkcVXi43MLQ1MnPQ3P6xY6c7eqSvL1C57jA1cU-FW_H9jdQqeHz-YHRyT8CIJYnrCGiFxlxgLxnDpBrQa_U5Yrp3Qy5Zmg1E5MZq00PDF5bDPqwM1YzJzK4zzJLKe30agENHYRVombMPDG3AEXM9NcOQlFxwysjGGSjhEd-ju1QSXd_6yjSLvQn4TZUg9c6uFNA7xjRNZWy14l5A_5n3pXWuf1Gt_dDejfNPRramWmWZYrYJSaWWWnOjOJUCqXvpk8HqNd7wrDA-rULylyL-vKxmhvcM6Lkx-uk2E08SEiXbqqrVMhfWQ1gQre6T35e3MUFUA9ASC54eMbbdhMKRfvOr1y4ICMCbCM1m_DX6F0918N7qErQ7Avpnto1Kxadx84Y2MehDf_G14Lduk priority: 102 providerName: Unpaywall |
| Title | In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon-γ T Cell Response |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19365543 https://www.proquest.com/docview/1290548274 https://www.proquest.com/docview/67128127 https://pubmed.ncbi.nlm.nih.gov/PMC2664463 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0005187&type=printable https://doaj.org/article/c7da4df9893a4c9c8adb2699f72bf151 http://dx.doi.org/10.1371/journal.pone.0005187 |
| UnpaywallVersion | publishedVersion |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: HH5 dateStart: 20060101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20060101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20061001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: ABDBF dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DIK dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: GX1 dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8FG dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1932-6203 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M48 dateStart: 20061201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLf2cYALYnytMIoPHOCQakkcOz4gtE0rA2nVhFapnCLbsbdKqVOSdtD_nufUCVQUwYFLVNlxE7-P-me_199D6DUTgAGE1gFRggZEqjyQodBBFAvJAF6LRLoD_csRvRiTT5NksoPamq1egPXWrZ2rJzWuisH3r6v34PDvmqoNLGwHDeal1YMGlKRsF-3D2hQ6Nv1L0sUVwLsp9X-g-9PIjQWq4fF3vKdFWW_DoL-nUt5b2rlYfRNF8cs6NXyIHniAiU_WFnGAdrR9hA68C9f4jeeZfvsYFR8tvpvelVjYHE_d50VVYp_ggUsD7S6PQOpKLeHFpjXustJxafFspeC3oOF6huc52onK6Kq0wY2YzQS-xi4mgKt1Dq5-gsbD8-uzi8AXXwhUEpFFQA3PpQKwl2oaKwG65irhmosoTXIax-pY5koxmUTShCqPNaiWhERzE5ooV0n8FO1ZEOshwjzSxwQswGjAPzI1XDP46pDAKCkJi3sobiWeKc9M7gpkFFkTbmOwQ1nLLnN6yryeeijoRs3XzBx_uf_UKbO71_FqNw1ldZN5N80UywXJDQcUJ4jiKhW5jCjnhrlpJmEPHTpTaB9QZ-4YL3FUqqSHjlrz2N79qusGD3YqEFaXyzqjzEUzI3jBZ2tb-jkdHlOAeyAgtmFlG3PY7LHT24YjHHAXbPRh5KCzx3-S0vP_IaUX6H4bdAvjI7S3qJb6JWC3heyjXTZhcE3PQncdfuij_dPz0dXnfnMa0m_cFdrGo6uTLz8AUHFTGA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqcigXRHl1oVAfQIJDto3t2OsDQmWh2qXdHtAW9Rb8CqwUJUuyodo_xYX_wW9inMe2Kyrg0lsUx4ln5svkiz2eQei5UMABlHMBM4oHTBsb6FC5gFClBdBrFWk_oT855aMz9uE8Ot9AP7q9MD6ssvOJtaO2ufFz5Pt-viTyOSvZm_m3wFeN8qurXQmNBhbHbnkBv2zl6_E7sO8LQo7eT4ejoK0qEJiIsEXAE2m1ARYzcJwaBUJIE0knFRlEllNqDrQ1RuiI6CQ0ljoYMwuZk0mYEGt8lQhw-bcYJdKHkA2Gq5AS8B2ct9vzqAj3WzT053nm-jVZ8oF7Vz5_dZUAn1U1zcvrGO6fgZpbVTZXywuVple-gkd30Z2WvuLDBm_baMNl99B26yBK_LLNYv3qPpqNM_xp9j3HKrO4Pl4UOW6SJZc4T_Ch3yBcaVeYCgY2K_G0i3nHeYYnSwOeps4kDc-r5y0TV-RZ8OsnnuKhS1P8sQnvdQ_Q2Y1Y4CHazECnOwhL4g4YgCtxQK30IJFOwK1DBr20ZoL2EO3UHZs26bmvvZHG9UqegJ-fRnGxN1LcGqmHglWveZP04x_Xv_WWXF3rU3bXJ_LiS9x6gNgIq5hNJBBExYw0A2U14VImwosZhT2043HQPaCMLxHfQ7sdNq5v3ls1g3PwKz4qc3lVxlz4hVICA3zUAOlSHEk5MElQkFiD2JoM6y3Z7GudfhwoHWMcevZXYPwvLT3-uxR7aGs0nZzEJ-PT4yfodrdqF9JdtLkoKvcUyN9CP6vfOIw-3_Qr_htz1nZr |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXRHl1oVAfQIKDd5vEsdcHhErL0qW0QmiLegt-wkpRsiQbqv1d3PgR_CbGeWy7ogIuva3ieON5ePzZM55B6CmXgAGktYRqyQhV2hAVSEvCSCoO8FrGyh_oHx2zgxP67jQ-XUM_u7swPqyys4m1oTa59mfkA39eEvuclXTg2rCID_ujV7NvxFeQ8p7WrpxGoyKHdnEG27fy5XgfZP0sDEdvJnsHpK0wQHQc0jlhThilAdEMLYu0BIKEjoUVMhzGhkWR3lFGa67iULlAm8jC-GlArXCBC432FSPA_F_jEWz1_C310dtuFQA7wlh7VQ9aB61m9Gd5Zvs1cPJBfBeWwrpigM-wmublZWj3z6DNG1U2k4szmaYXVsTRbXSrhbJ4t9G9DbRmsztoozUWJX7eZrR-cRdNxxn-NP2eY5kZXP-eFzluEieXOHd4118WrpQtdAUDm5Z40sW_4zzDRwsNVqfOKg3fq88wnS3yjPz6gSd4z6Yp_tiE-tp76ORKJHAfrWfA002ERWh3KCiaswCz1NAJy-GvAwq9lKI86qGoY3ei2wTovg5HmtRePQ4boYZxiRdS0gqph8iy16xJAPKP9197SS7f9em76wd58SVprUGiuZHUOAFgUVIt9FAaFTIhHPdkxkEPbXo96D5QJufa30NbnW5c3ry9bAZD4b0_MrN5VSaMe6dpCAN80CjSOTkiYoAqgUF8RcVWaFhtyaZf61TkAO8oZdCzv1TG_-LSw79TsY2uw-RO3o-PDx-hm50DL4i20Pq8qOxjwIFz9aSecBh9vuoZ_hu9FnrJ |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLXKdAEboLw6UMALFrBwOolf4-VQURWkVghNUVmgyHYcMSJKRpMEVBb8FP_BN3GdOAMDRcCCXRT7OvbxjXPsa58g9Ehq4ADaOcKsFoQZmxETa0cSqo0Eeq258Qv6xyfi6JS9OONnW-jtcBYmIAhzxKKqu0i-v6hKtx-Q3Pd6RX30NIqpjAeLaAmZoo6SwAjeKQ75lbHGH0C6hLYFh8n1CG2fnrycvekjzQkRyYSG43S_K2njc9Wp-nsVVKjSRYz0142Vl9tyqc8_6qL44at1eA19Htrbb1Z5H7WNieynn6Qg_xsg19HVwHfxrC9lB2258gbaCSNKjR8H2esnN9HieYlfLz5UWJcZ7q6bVYV7deUaVzme-RPFrXEr20LdFjWeD5vkcVXi43MLQ1MnPQ3P6xY6c7eqSvL1C57jA1cU-FW_H9jdQqeHz-YHRyT8CIJYnrCGiFxlxgLxnDpBrQa_U5Yrp3Qy5Zmg1E5MZq00PDF5bDPqwM1YzJzK4zzJLKe30agENHYRVombMPDG3AEXM9NcOQlFxwysjGGSjhEd-ju1QSXd_6yjSLvQn4TZUg9c6uFNA7xjRNZWy14l5A_5n3pXWuf1Gt_dDejfNPRramWmWZYrYJSaWWWnOjOJUCqXvpk8HqNd7wrDA-rULylyL-vKxmhvcM6Lkx-uk2E08SEiXbqqrVMhfWQ1gQre6T35e3MUFUA9ASC54eMbbdhMKRfvOr1y4ICMCbCM1m_DX6F0918N7qErQ7Avpnto1Kxadx84Y2MehDf_G14Lduk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vivo+and+in+vitro+effects+of+antituberculosis+treatment+on+mycobacterial+interferon-gamma+T+cell+response&rft.jtitle=PloS+one&rft.au=Ilaria+Sauzullo&rft.au=Fabio+Mengoni&rft.au=Miriam+Lichtner&rft.au=Anna+Paola+Massetti&rft.date=2009-04-13&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.eissn=1932-6203&rft.volume=4&rft.issue=4&rft.spage=e5187&rft_id=info:doi/10.1371%2Fjournal.pone.0005187&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c7da4df9893a4c9c8adb2699f72bf151 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |